Abstract

The present invention relates to the development of novel isoindoline derivatives as activators of AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in cellular metabolism. The compounds, with original chemical structure, can be usefully employed for the prevention and treatment of metabolic disorders, such as type II diabetes and obesity, as well as immune-mediated inflammatory diseases and cancer.

Research Institution

Università di Pisa

Numero di pubblicazione

WO2018189679A1

TRL

N.A.

Technologies, Systems, Applications

Biomedical, New drugs development